ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Randomized Trial"

  • Abstract Number: 1636 • ACR Convergence 2023

    Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study

    E. William St. Clair1, Liangwei Wang2, Ilias Alevizos2, William A. Rees2, Alan Baer3, Wan-Fai Ng4, Ghaith Noaiseh5 and Chiara Baldini6, 1Duke University Medical Center, Durham, NC, 2Horizon Therapeutics, Rockville, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 5University of Kansas Medical Center, Kansas City, KS, 6University of Pisa, Pisa, Italy

    Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
  • Abstract Number: 2155 • ACR Convergence 2023

    The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies

    Peter C. Taylor1, Arthur Kavanaugh2, Peter Nash3, Janet Pope4, Georg Pongratz5, Bruno Fautrel6, Rieke Alten7, Ken Hasegawa8, Shangbang Rao9, Dick de Vries10, Pieter-Jan Stiers11, Chris Watson12 and René Westhovens13, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 3School of Medicine, Griffith University, Brisbane, Australia, 4University of Western Ontario, London, ON, Canada, 5Faculty of Medicine, Regensburg University, Regensburg, Germany, Regensburg, Germany, 6Sorbonne Université APHP, Paris, France, 7Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 8Global Medical Affairs Research, Gilead Sciences, Inc., Foster City, CA, 9Biostatistics, Gilead Sciences, Inc., Foster City, CA, 10Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, 11Biostatistics, Galapagos NV, Mechelen, Belgium, 12Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, 13Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium

    Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post hoc analysis…
  • Abstract Number: L05 • ACR Convergence 2022

    Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase

    Ruth Wittoek1, August Verbruggen2, Tine Vanhaverbeke2 and Dirk Elewaut3, 1Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Oost-Vlaanderen, Belgium, 2Ghent University Hospital, Ghent, Belgium, 3Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

    Background/Purpose: Erosive hand osteoarthritis (OA) is a disabling disease with limited therapeutic options. Denosumab, a Receptor Activator of Nuclear Factor kappa-b Ligand inhibitor, affects bone…
  • Abstract Number: L07 • ACR Convergence 2022

    Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study

    Di Wu1, Jing Li1, Dong Xu1, Li Wang1, Jianmin Fang2, Dan Ross3 and Fengchun Zhang4, 1Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, 2Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, 3RemeGen Co., San Diego, CA, 4Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China

    Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
  • Abstract Number: L14 • ACR Convergence 2022

    Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

    Xenofon Baraliakos1, Atul Deodhar2, Désirée van der Heijde3, Marina Magrey4, Walter Maksymowych5, Tetsuya Tomita6, Huji Xu7, Marga Oortgiesen8, Ute Massow9, Carmen Fleurinck10, Alicia M Ellis8, Tom Vaux11, Julie Shepherd-Smith11, Alexander Marten9 and Lianne S Gensler12, 1Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, 2Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, 7Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), 8UCB Pharma, Morrisvile, NC, 9UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, 10UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 11UCB Pharma, Slough, United Kingdom, 12Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
  • Abstract Number: L15 • ACR Convergence 2022

    Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

    Xenofon Baraliakos1, Mikkel Østergaard2, Denis Poddubnyy3, Désirée van der Heijde4, Atul Deodhar5, Pedro M. Machado6, Victoria Navarro-Compán7, Kay Geert Hermann8, Mitsumasa Kishimoto9, Eun Young Lee10, Lianne S Gensler11, Uta Kiltz1, Marco Eigenmann12, Patricia Pertel13, Aimee Readie14, Hanno B. Richards12, Brian Porter15 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 6Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 7Department of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 8Department of Radiology, University Hospital Charité - Campus Mitte, Charitéplatz, Berlin, Germany, 9Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 10Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, 11Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 12Novartis Pharma AG, Basel, Switzerland, 13Novartis Pharma AG, Reinach, Switzerland, 14Novartis Pharmaceuticals Corporation, East Hanover, NJ, 15Novartis Pharmaceuticals Corporation, Far Hills, NJ

    Background/Purpose: Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in…
  • Abstract Number: 0229 • ACR Convergence 2022

    The Effect of Interactive E-learning on Resident’s Practical Performance in Musculoskeletal Ultrasound- a Randomized Study

    Stine Maya Dreier Carstensen1, Søren Just2, Marie Velander3, Lars Konge4, Martin Slusarczyk Hubel5, Thiusius Rajeeth Savarimuthu5, Mogens Pfeiffer Jensen6, Mikkel Østergaard7 and Lene Terslev8, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen University Hospital – Rigshospitalet Glostrup, Glostrup, Denmark, 2Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, 3Section of Rheumatology, Department of Medicine, Svendborg Hospital - Odense University Hospital (OUH), Svendborg, Denmark, 4Copenhagen Academy for Medical Education and Simulation The Capital Region of Denmark, Copenhagen, Denmark, 5SDU Robotics, Mærsk Mc-Kinney Møller Instituttet, Syddansk Universitet, Odense, Odense, Denmark, 6Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen University Hospital – Rigshospitalet Glostrup, Copenhagen, Denmark, 7Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 8Copenhagen University Hospital Glostrup, Glostrup, Denmark

    Background/Purpose: Musculoskeletal ultrasound (MSUS) is a complex procedure to master and requires both extensive theoretical knowledge and hands-on training. E-learning supplements hands-on training by providing…
  • Abstract Number: 1113 • ACR Convergence 2022

    Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study

    Thomas Dörner1, Antónia Szántó2, Jui-Cheng Tseng3, Martin Kaul4, Ilona Pylvaenaeinen5, Malika Hanser6, Nasri Abdallah6, Bruno Cenni6 and Richard Siegel6, 1Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 2Debreceni Egyetem Klinikai Centrum, Debrecen, Hungary, 3Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 4Independent Consultant, Neustadt, Germany, 5Early Development Analytics, Novartis Pharmaceutical AG, Basel, Switzerland, 6Novartis Institutes for BioMedical Research, Basel, Switzerland

    Background/Purpose: Sjögren's syndrome (SS) is a systemic autoimmune disease of unknown etiology characterized by B-cell hyperactivation, lymphoid infiltration, progressive destruction of exocrine glands, and various…
  • Abstract Number: 2008 • ACR Convergence 2022

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs

    Alan Kivitz1, Liangwei Wang2, Ilias Alevizos2, Michele Gunsior2, Judith Falloon2 and Gabor Illei3, 1Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 2Horizon Therapeutics, Gaithersburg, MD, 3Horizon Therapeutics, Rockville, MD

    Background/Purpose: Dazodalibep (DAZ), a non-antibody biologic antagonist of CD40L, led to higher/durable response rates vs. placebo (PBO) in a double-blind, Phase 1b trial of patients…
  • Abstract Number: 0286 • ACR Convergence 2022

    Efficacy and Safety of Upadacitinib in Patients Across Races with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3 Clinical Trials

    Grace Wright1, Eduardo Mysler2, Iris Navarro-Millan3, Yoshiya Tanaka4, Samuel Anyanwu5, Jianzhong Liu5, Oishi Tanjinatus5, Andrew Garrison5 and Alvin Wells6, 1Association of Women in Rheumatology, New York, NY, 2Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, 3Weill Cornell Medicine, New York, NY, 4University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 5AbbVie, Inc., North Chicago, IL, 6Aurora Rheumatology and Immunotherapy Center, Franklin, WI

    Background/Purpose: RA affects diverse patient populations with varying disease severity and treatment responses. However, data on treatment response to advanced therapies by race are limited.1…
  • Abstract Number: 1229 • ACR Convergence 2022

    Erosion Score and Erosive Joint Number Using Radiography: Clinical Implications in Patients with ACPA+ Early RA Treated with Abatacept

    Chahin Pachai1, Sean E Connolly2, Yoshiya Tanaka3, Vivian Bykerk4, Tom Huizinga5, Gustavo Citera6, Clifton O. Bingham III7, Shuyan Du1, Godehard Hoexter8, Paul Emery9, Subhashis Banerjee1 and Roy Fleischmann10, 1Bristol Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Morrisville, PA, 3University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 4Hospital for Special Surgery, New York, NY, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, 7Johns Hopkins University, Baltimore, MD, 8Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany, 9Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 10University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Inhibition of structural joint damage progression is a key outcome measure in RA clinical trials. This can be assessed by progression of joint erosion…
  • Abstract Number: 2116 • ACR Convergence 2022

    Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis

    Juan Josè de Agustin1, Gustavo Añez1, delia reina2, Sergi Heredia3, Felipe Julio Ramirez Garcia4, Andrea Cuervo5, Jesus Rodriguez6, Carmen Moragues6, Patricia Moya7, Mireia Moreno8, Marta Arévalo8, Manel Pujol9, Georgina Salvador9, Noemi Busquets10, andres Ponce10, Ana Maria Laiz Alonso7 and MAria Pascual Pastor11, 1Vall D'hebron University Hospital, Barcelona, Spain, 2Complex Hospitalari Moisès Broggi, Sant Joan Despí, Catalonia, Spain, 3Complex Hospitalari Moisès Broggi, Sant Joan Despi, Catalonia, Spain, 4Hospital Clínic, Barcelona, Spain, 5Hospital Clínico y Provincial de Barcelona, Barcelona, Spain, 6Hospital Bellvitge, Hospitalet de Llobregat, Spain, 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 8Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, 9Hospital Universitario MútuaTerrassa, Terrassa, Spain, 10Hospital General de Granollers, Granollers, Spain, 11Hospital Universitari Vall d'Hebron, Barcelona, Spain

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease involving joint and enthesis disease. Ultrasound (US) has demonstrated its useful tool for the diagnosis of…
  • Abstract Number: 0287 • ACR Convergence 2022

    Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy

    Christina Charles-Schoeman1, Roy Fleischmann2, Stephen Hall3, Arthur Kavanaugh4, Andrea Rubbert-Roth5, Ryan DeMasi6, Sara Penn6, Andrew Garrison6, Samuel Anyanwu6, Radames Sierra-Zorita7 and Ricardo Xavier8, 1Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, 2University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 3Emeritus Research and Monash University, Melbourne, Australia, 4University of California San Diego, La Jolla, CA, 5Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, 6AbbVie, Inc., North Chicago, IL, 7University of Puerto Rico, San Juan, Puerto Rico, 8Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

    Background/Purpose: Early predictors of response to treatment with upadacitinib (UPA), an oral Janus kinase inhibitor, could help to optimize a treat-to-target approach in patients with…
  • Abstract Number: 1424 • ACR Convergence 2022

    Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial

    Joanna KEDRA1, Lina El Houari1, Florence Tubach1, Benjamin granger1 and Bruno Fautrel2, 1Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, 2Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France

    Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
  • Abstract Number: 2146 • ACR Convergence 2022

    Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years

    Philip J Mease1, Rodrigo Luppino Assad2, Shigeyoshi Tsuji3, Pascal Richette4, Arathi Setty5, Erin McDearmon-Blondell6, Tianming Gao5, Sandra Ciecinski6 and Filip Van den bosch7, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, 3Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, 4Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc., Mettawa, IL, 7Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium

    Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology